CTLP Lawsuits

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Published August 25, 2025 at 12:03 PM

As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035

Related Questions

How will the settlement and delayed generic entry until 2035 affect Catalyst Pharmaceuticals' projected cash flows and valuation? What is the market's likely reaction to the news in terms of CTLP stock price volatility and volume in the short term? How does this settlement compare to similar patent litigation outcomes for other rare‑disease drug companies and what are the broader competitive implications?

Find similar articles on Candlesense globenewswire